Literature DB >> 15644191

Delivery of siRNA and siRNA expression constructs to adult mammals by hydrodynamic intravascular injection.

David L Lewis1, Jon A Wolff.   

Abstract

Extensive use of RNA interference in mammals has been hindered by the inability to effectively deliver small interfering RNAs (siRNAs) or DNA-based constructs designed to express siRNAs. In this chapter, we describe the high-pressure or hydrodynamic intravascular injection technique used to deliver these nucleic acids to mice and nonhuman primates. Emphasis is placed on the use of this technique for delivery to the liver.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15644191     DOI: 10.1016/S0076-6879(04)92020-4

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  19 in total

Review 1.  Ligand-targeted delivery of therapeutic siRNA.

Authors:  Yutaka Ikeda; Kazunari Taira
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

2.  PGC-1alpha controls hepatitis B virus through nutritional signals.

Authors:  Amir Shlomai; Nir Paran; Yosef Shaul
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-16       Impact factor: 11.205

3.  Bioluminescence imaging allows monitoring hepatitis C virus core protein inhibitors in mice.

Authors:  Juan Du; Fang Zhao; Yong Zhou; Hu Yan; Xiang-guo Duan; Sheng-qiang Liang; Ying-li Wang; Qiu-xia Fu; Xiao-hui Wang; Jian-chun Peng; Lin-sheng Zhan
Journal:  PLoS One       Date:  2010-11-18       Impact factor: 3.240

Review 4.  Engineering RNA for targeted siRNA delivery and medical application.

Authors:  Peixuan Guo; Oana Coban; Nicholas M Snead; Joe Trebley; Steve Hoeprich; Songchuan Guo; Yi Shu
Journal:  Adv Drug Deliv Rev       Date:  2010-03-15       Impact factor: 15.470

5.  Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits.

Authors:  M DiFiglia; M Sena-Esteves; K Chase; E Sapp; E Pfister; M Sass; J Yoder; P Reeves; R K Pandey; K G Rajeev; M Manoharan; D W Y Sah; P D Zamore; N Aronin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-16       Impact factor: 11.205

6.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

Authors:  Jiehua Zhou; Haitang Li; Shirley Li; John Zaia; John J Rossi
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

7.  Gene therapy for arthritis--where do we stand?

Authors:  Yuti Chernajovsky
Journal:  Arthritis Res Ther       Date:  2005-09-14       Impact factor: 5.156

8.  Delivery of RNAi reagents in murine models of obesity and diabetes.

Authors:  Denise M Wilcox; Ruojing Yang; Sherry J Morgan; Phong T Nguyen; Martin J Voorbach; Paul M Jung; Deanna L Haasch; Emily Lin; Eugene N Bush; Terry J Opgenorth; Peer B Jacobson; Christine A Collins; Cristina M Rondinone; Terry Surowy; Katherine T Landschulz
Journal:  J RNAi Gene Silencing       Date:  2006-11-29

9.  Establishment of a positive-readout reporter system for siRNAs.

Authors:  Wei-Li Liu; Douglas P Owen; Kerry D Fisher; Leonard W Seymour; Mark Stevenson
Journal:  J RNAi Gene Silencing       Date:  2009-06-12

10.  RNA interference targeting the platelet-derived growth factor receptor beta subunit ameliorates experimental hepatic fibrosis in rats.

Authors:  Si-Wen Chen; Xing-Rong Zhang; Chong-Ze Wang; Wei-Zhong Chen; Wei-Fen Xie; Yue-Xiang Chen
Journal:  Liver Int       Date:  2008-05-03       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.